Cipla faces downgrade after USFDA warning letter

B&K Securities airs concerns considering Cipla’s significant exposure to the US market, constituting 28% of consolidated sales

Related Keywords

India ,Cipla Pithampur ,Drug Administration ,Cipla ,Import Alert ,Usfda Warning Letter ,Dharma ,Pharma Sector ,Harma In India ,